权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Biomarkers for parkinsonian disorders in CNS-originating extracellular vesicles

中枢神经系统来源的细胞外囊泡中帕金森病的生物标志物

基本信息

批准号：
10662918
负责人：
GAL BITAN
金额：
$ 237.47万
依托单位：
UNIVERSITY OF CALIFORNIA LOS ANGELES
依托单位国家：
美国
项目类别：
财政年份：
2023
资助国家：
美国
起止时间：
2023-04-01 至 2026-03-31
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10662918
关键词：
Address Agreement Anxiety Autonomic Dysfunction Autopsy Behavior Disorders Biochemical Biological Markers Blood Blood Tests Brain Caregivers Cells Central Nervous System Central Nervous System Diseases Cerebrospinal Fluid Cessation of life Clinic Clinical Clinical Trials Confusion Consult Data Dementia Dementia with Lewy Bodies Development Diagnosis Diagnostic tests Disease Disease Progression Family Future Goals Immunoprecipitation Intervention Lead Left Light Measures Methodology Modeling Movement Disorders Multiple System Atrophy Nature Neural Cell Adhesion Molecule L1 Neurodegenerative Disorders Neurologic Neurologist Neurons New York Oligonucleotides Parkinson Disease Parkinsonian Disorders Pathologic Patients Periodicity Physicians Plasma Positron-Emission Tomography Progressive Supranuclear Palsy Protocols documentation Public Health REM Sleep Radioisotopes Reporting Research Research Design Sampling Sampling Studies Sensitivity and Specificity Serum Specialist Specificity Spinal Puncture Stress Symptoms Tauopathies Testing Training Translating Universities Validation alpha synuclein biobank biomarker panel biomarker performance brain tissue candidate marker cohort corticobasal syndrome cost effective diagnostic accuracy diagnostic tool diagnostic value effective therapy experience extracellular vesicles imaging biomarker improved inclusion criteria liquid biopsy minimally invasive neurofilament patient response patient stratification prospective single photon emission computed tomography success sulfated glycoprotein 2 synucleinopathy tau Proteins

项目摘要

Summary Many cases of Parkinson’s disease, and even more so atypical parkinsonian disorders, are misdiagnosed. Misdiagnosis not only causes high stress and anxiety to patients, their families, and their caregivers, but also is a major impediment to development of effective therapy for these diseases. Recently, we have demonstrated that the α-synuclein concentration in extracellular vesicles (EVs) immunoprecipitated from serum or plasma using oligodendroglial and neuronal markers, and in particular the ratio between the α-synuclein concentrations in the two types of EVs, is a sensitive biomarker for distinguishing between Parkinson’s disease and multiple system atrophy. This liquid biopsy approach requires only a minimally invasive blood draw and could lead to a major advancement in developing diagnostic tests for these diseases. Here, we propose to build upon these recent findings by constructing a biomarker panel, including several additional candidate markers, and apply the panel to two additional atypical parkinsonian syndromes—progressive supranuclear palsy and corticobasal syndrome. Serum samples for the study will be obtained from several national biorepositories as well as collected locally, prospectively, in expert clinics. The study design emphasizes biomarker analysis within the first two years of diagnosis, and in prodromal synucleinopathy, to test the utility of the biomarker panel when it is most needed. An additional goal of the project is to develop methodology for validating the cellular origin of the EVs, an urgent unmet need in the field. Success of the project will lead both to an advancement of research on biomarkers for CNS diseases using a minimally invasive liquid biopsy that can be translated into clinical use in the near future.

概括许多帕金森病病例，尤其是非典型帕金森病病例，都被误诊。误诊不仅给患者、患者家属和护理人员带来巨大的压力和焦虑，而且开发这些疾病的有效疗法的主要障碍。最近，我们展示了使用免疫沉淀法从血清或血浆中免疫沉淀细胞外囊泡 (EV) 中的 α-突触核蛋白浓度少突胶质细胞和神经元标记物，特别是 α-突触核蛋白浓度之间的比率两种类型的 EV，是区分帕金森病和多系统疾病的敏感生物标志物萎缩。这种液体活检方法仅需要微创抽血，并且可能导致重大在开发这些疾病的诊断测试方面取得了进展。在这里，我们建议以最近这些通过构建生物标记物组（包括几个额外的候选标记物）来得出结果，并应用该组另外两种非典型帕金森综合征——进行性核上性麻痹和皮质基底节综合征。用于研究的血清样本将从几个国家生物样本库获得以及在当地收集，前瞻性地，在专家诊所。研究设计强调在研究的头两年内进行生物标志物分析诊断和前驱突触核蛋白病，以在最需要时测试生物标志物组的效用。该项目的另一个目标是开发验证电动汽车细胞起源的方法，这是一个紧迫的任务领域内未满足的需求。该项目的成功将推动生物标志物研究的进步使用微创液体活检治疗中枢神经系统疾病可以在不久的将来转化为临床应用。